A phase II trial of CC-122 in patients with non-Hodgkin's lymphoma

Trial Profile

A phase II trial of CC-122 in patients with non-Hodgkin's lymphoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Avadomide (Primary)
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 27 Jul 2017 According to Celgene Corporation media release, this trial is expected to initiate in second half of 2017.
    • 14 Jan 2016 New trial record
    • 11 Jan 2016 Data from this trial is expected in 2016, according to Celgene Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top